Elicio Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	13.62	7.8	88.76	34.61	5.57	25.51
Cash & Cash Equivalents	13.62	7.8	88.76	34.61	5.57	25.51
Cash Growth	74.63%	-91.22%	156.47%	521.20%	-78.16%	-
Receivables	0	0	0.81	0	0.44	0.11
Other Current Assets	2.73	2.92	1.69	7.69	0.1	0.06
Total Current Assets	16.35	10.72	91.25	42.3	6.11	25.68
Property, Plant & Equipment	7.28	8.5	4.44	4.23	4.78	0.02
Long-Term Investments	0	0	0.72	0.82	1	0.93
Other Long-Term Assets	3.52	3.45	0.11	0	0	0
Total Long-Term Assets	10.8	11.95	5.27	5.05	5.78	0.95
Total Assets	27.15	22.66	96.51	47.35	11.89	26.63
Accounts Payable	4.37	2.81	4.71	5.58	11.24	0.53
Deferred Revenue	0	0	2.3	29.81	0	0
Current Debt	0.91	0.69	0.95	52.04	6.88	0
Other Current Liabilities	4.49	3.37	3.33	20.02	8.46	6.82
Total Current Liabilities	9.77	6.87	11.3	107.45	26.58	7.36
Long-Term Debt	6.01	6.79	3.71	4.48	3.9	0
Other Long-Term Liabilities	0	0.09	0	25.87	0	0.36
Total Long-Term Liabilities	6.01	6.88	3.71	30.35	3.9	0.36
Total Liabilities	15.77	13.75	15.01	137.8	30.47	7.72
Total Debt	6.92	7.48	4.66	56.52	10.78	0
Debt Growth	-7.54%	60.47%	-91.75%	424.43%	-	-
Retained Earnings	-142.2	-107.01	-215.14	-160.56	-80.46	-39.8
Comprehensive Income	-0.2	0	-0.1	-0.33	0	0
Shareholders' Equity	11.37	-102.15	81.51	-90.45	-18.59	18.91
Net Cash / Debt	6.7	0.32	84.09	-21.92	-5.21	25.51
Net Cash / Debt Growth	2019.94%	-99.62%	-	-	-	-
Net Cash Per Share	1.32	1.00	29.77	-14.85	-3.61	26.34
Working Capital	6.58	3.85	79.95	-65.15	-20.47	18.32
Book Value Per Share	2.25	-323.25	28.86	-61.27	-12.88	19.52

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).